Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non–Small Cell Lung Cancer

Departments of *Radiotherapy

†Oncology, The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), Jinan, Shandong Province, China

A.X.Z. is the guarantor of integrity of the entire study and contributed to the study concepts, study design, definition of intellectual content, manuscript editing, and review. Z.X.Z. contributed to the literature research, clinical studies, experimental studies, manuscript preparation. A.X.Z. and Z.X.Z. contributed to the data acquisition, data analysis, statistical analysis, read, and approved the final manuscript.

Supported by the study of the predictive value of lung immune prognostic index (LIPI) among patients with advanced non–small cell lung cancer treated with immunotherapy (Shandong Provincial Natural Science Foundation Youth Project, NO.ZR2020QH178).

The authors declare no conflicts of interest.

Correspondence: Aixia Zhang, MSc, Department of Oncology, The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences), No. 38, Wu Yingshan Road, Tianqiao District, Jinan 250031, Shandong Province, China. E-mail: [email protected]

留言 (0)

沒有登入
gif